Recent comparative studies have begun to address which tau antibodies may be the most efficacious at blocking seeding from human Alzheimer’s disease material in vitro (Nobuhara et al., 2017; Courade et al., 2018; Vandermeeren et al., 2018). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.